Overview

DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension

Status:
Terminated

Trial end date:
2010-05-01

Target enrollment:

Participant gender:

Summary

This is a double-blind, active-controlled, long-term study of a new experimental drug called darusentan. Darusentan in not currently approved by the United States Food and Drug Administration (FDA), which means that a doctor cannot prescribe this drug. The purpose of this study is to evaluate the long-term safety of darusentan (optimized dose) as compared to an active control, administered orally.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Darusentan
Guanfacine
LU 135252